Role of the Renin-Angiotensin-Aldosterone system in the pathogenesis of atherosclerosis

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 981-1004

  Durante, Alessandro ^a   Peretto, Giovanni ^a   Laricchia, Alessandra ^a   Ancona, Francesco ^a   Spartera, Marco ^a   Mangieri, Antonio ^a   Cianflone, Domenico ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Aldosterone; Angiotensin; Atherosclerosis; RAAS; Renin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; PRORENIN; PRORENIN RECEPTOR; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MOLECULAR INTERACTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84857136034     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436467     Document Type: Review

References (294)

1. Gomez RA, Chevalier RL, Everett AD, et al. Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol 1990; 259: F660-5.
2. Nushiro N, Ito S, Misawa S, Abe K. Renin release from microdissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Nihon Jinzo Gakkai Shi 1992; 34: 1113-6.
3. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman'sThe Pharmacological Basis of Therapeutics 11th ed. McGraw-Hill.
4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
5. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
6. Goodfriend TL, Elliott ME, Catt KJ, et al. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-54.
7. Stern N, Golub M, Nozawa K, et al. Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade. Am J Physiol 1989; 257: H434-43.
8. Denton KM, Fennessy PA, Alcorn D, et al. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 1992; 262: F367-72.
9. Vallotton MB, Gerber-Wicht C, Dolci W, Wüthrich RP. Interaction of vasopressin and angiotensin II in stimulation of prostacyclin synthesis in vascular smooth muscle cells. Am J Physiol 1989; 257: E617-24.
10. Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery incardiovascular disease. Drug Discov Today 2011; 16: 22-34.
11. Ohyama K, Yamano Y, Sano T, et al. Disulfide bridges in extracellular domains of angiotensin II receptor type IA. Regul Pept 1995; 57: 141-7.
12. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution,signaling and function. Clin Sci 2001; 100: 481-92.
13. Capponi AM. Distribution and signaltransduction of angiotensin II AT1 and AT2 receptors. Blood Press Suppl 1996; 2: 41-6.
14. Schieffer B, Paxton WG, Marrero MB and Bernstein KE. Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Hypertension 1996; 27: 476-80.
15. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II--induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993; 73: 424-38.
16. Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.
17. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276: 39721-6.
18. Adachi Y, Saito Y, Kishimoto I, et al. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 2003; 107: 2406-8.
19. Suzuki J, Iwai M, Nakagami H, et al. Role of angiotensin IIregulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002; 106: 847-53.
20. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-35.
21. Katada J, and Majima M. (2002) AT(2) receptor-dependent vasodilation ismediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002;136: 484-91.
22. Bergaya S, Hilgers RH, Meneton P, et al. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res 2004; 94: 1623-9.
23. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48: 316-22.
24. Lemarie CA and Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010;11: 19-31.
25. Yan X, Price RL, Nakayama M, et al. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 2003; 285: H2179-87.
26. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992; 182: 388-94.
27. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120: 292-316.
28. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the reninangiotensin system. Curr Opin Nephrol Hypertens 2007; 16: 122-8.
29. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
30. Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806-13.
31. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006; 47: 996-1002.
32. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin IIinduced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-42.
33. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001; 12: 157-62.
34. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993; 264: R917-23.
35. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005; 45: 960-6.
36. Padia SH, Howell NL, Siragy HM, Carey RM. Hypertension. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat 2006; 47: 537-44.
37. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 2003; 86: 344-50.
38. Caron AZ, Arguin G, Guillemette G. Angiotensin IV interacts with a juxtamembrane site on AT(4)/IRAP suggesting an allosteric mechanism of enzyme modulation. Regul Pept 2003; 113: 9-15.
39. Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004; 61: 2728-37.
40. Esteban V, Ruperez M, Sánchez-López E, et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 2005; 96: 965-73.
41. Chen S, Patel JM, Block ER. Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release. Am J Physiol Lung Cell Mol Physiol 2000; 279: L849-56.
42. Kramár EA, Harding JW, Wright JW. Angiotensin II-and IV induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 1997; 68: 131-8.
43. Hill-Kapturczak N, Kapturczak MH, Block ER, et al. Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. J Am Soc Nephrol 1999; 10: 481-91.
44. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-800.
45. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-10.
46. Grossmann C, Benesic A, Krug AW, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 2005; 19: 1697-710.
47. Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43: 352-7.
48. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligandstimulated nitric oxide production in endothelial cells. Hypertens Res 2008; 31: 1811-20.
49. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47: 650-5.
50. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 103: 2400-6.
51. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-14.
52. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. J Nat Med 2007;13:189-97.
53. Skøtt O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease--friend or foe? Pharmacol Ther 2006; 111: 495-507.
54. Jeong Y, Chaupin DF, Matsushita K, et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 2009, 106: 3782-7.
55. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17: 199-204.
56. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-73.
57. Kotlyar E, Vita JA, Winter MR, et al. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 2006; 12: 122-7.
58. Benard L, Milliez P, Ambroisine ML, Messaoudi S, Samuel JL, Delcayre C. Effects of aldosterone on coronary function. Pharmacol Rep 2009; 61: 58-66.
59. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985; 63:1522-7.
60. Ullian ME, Fine JJ. Mechanisms of enhanced angiotensin IIstimulated signal transduction in vascular smooth muscle by aldosterone. J Cell Physiol 1994; 161: 201-8.
61. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137-9.
62. Min LJ, Mogi M, Iwanami J, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76: 506-16.
63. Montezano AC, Callera GE, Yogi A, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-8.
64. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-42.
65. Lemarié CA, Simeone SM, Nikonova A, et al. Aldosteroneinduced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009; 105: 852-9.
66. Sealey JE, Glorioso N, Itskovitz J, Troffa C, Cholst I, Rosenwaks Z. Plasma prorenin during early pregnancy: ovarian secretion under gonadotropin control? Hypertens Suppl 1986; 4: S92-5.
67. Danser AH, van den Dorpel MA, Deinum J, et al. Prorenin in vitreous and subretinal fluid of the human eye. Clin Exp Hypertens A 1988; 10: 1297-9.
68. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. J Renin Angiotensin Aldosterone Syst 2005; 6: 163-5.
69. Krop M, de Bruyn JH, Derkx FH, Danser AH. Renin and prorenin disappearance in humans post-nephrectomy: evidence for binding? Front Biosci 2008; 13: 3931-9.
70. Neves FA, Duncan KG, Baxter JD. Cathepsin B is a prorenin processing enzyme. Hypertension 1996; 27: 514-7.
71. Reudelhuber TL, Ramla D, Chiu L, Mercure C, Seidah NG. Proteolytic processing of human prorenin in renal and non-renal tissues. Kidney Int 1994; 46: 1522-4.
72. Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-9.
73. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69: 1503-6.
74. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am J Physiol Heart Circ Physiol 2008; 295: H1117-H1121.
75. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-27.
76. Saris JJ, Derkx FH, De Bruin RJ, et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Circ Physiol 2001; 280: H1706-15.
77. Jan Danser AH, Saris JJ. Prorenin uptake in the heart: a prerequisite for local angiotensin generation? J Mol Cell Cardiol 2002; 34: 1463-72.
78. Peters J, Farrenkopf R, Clausmeyer S, et al. Functional significance of prorenin internalization in the rat heart. Circ Res 2002; 90: 1135-41.
79. Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr Opin Pharmacol 2008; 8: 127-32.
80. Cousin C, Bracquart D, Contrepas A, Nguyen G. Potential role of the (pro)renin receptor in cardiovascular and kidney diseases. J Nephrol 2010; 23: 508-13.
81. Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-8.
82. Sakoda M, Ichihara A, Kaneshiro Y, et al. (Pro)renin receptormediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139-46.
83. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-13.
84. Hitom H, Liu G, Nishiyama A. Role of (pro)renin receptor in cardiovascular cells from the aspect of signaling. Front Biosci 2010; 2:1246-9.
85. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010; 37: 277-82.
86. Burcklé CA, Jan Danser AH, Müller DN, et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006; 47: 552-6.
87. Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70: 641-6.
88. Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18: 1789-95.
89. Hirose T, Hashimoto M, Totsune K, et al. Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens 2009; 22: 294-9.
90. Muller DN, Klanke B, Feldt S, et al. (Pro)renin receptor peptide inhibitor handle-region peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-81.
91. Peters B, Grisk O, Becher B, et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26: 102-9.
92. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am J Physiol Heart Circ Physiol 2008; 295: H1117-H1121.
93. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-6.
94. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004; 44: 335-9.
95. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci 2002, 103: 131-6.
96. Kranzhöfer R, Browatzki M, Schmidt J, Kübler W. Angiotensin II activates the proinflammatory transcription factor nuclear factorkappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-8.
97. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensinconverting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
98. Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-9.
99. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-22.
100. Shagdarsuren E, Wellner M, Braesen JH, et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97: 716-24.
101. Hirono Y, Yoshimoto T, Suzuki N, et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007; 148: 1688-96.
102. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35: 353-9.
103. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15: 1295-302.
104. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-15.
105. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
106. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
107. Martorana PA, Ruetten H, Goebel B, et al. Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog. Basic Res Cardiol 1999; 94: 238-45.
108. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18: S110-5.
109. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1992; 20: 473-7.
110. Keidar S, Attias J, Coleman R, Wirth K, Schölkens B, Hayek T. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. Cardiovasc Pharmacol 2000; 35: 64-72.
111. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol 1999; 128: 523-9.
112. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
113. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebocontrolled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438-43.
114. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748-54.
115. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.
116. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
117. Baldasseroni S, Urso R, Orso F, et al. Comparative study of ACEinhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-6.
118. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
119. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
120. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.
121. Schieffer B, Bünte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-8.
122. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34: 2922-9.
123. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110: 1103-7.
124. Trevelyan J, Brull DJ, Needham EW, Montgomery HE, Morris A, Mattu RK. Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol 2004; 94: 564-9.
125. Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 2004; 15: 211-7.
126. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003; 305: 846-53.
127. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.
128. Kher V. Renin inhibition--benefit beyond hypertension control. J Assoc Physicians India 2009; 57: 518-20, 525.
129. Ismail H, Mitchell R, McFarlane SI, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep 2010; 10: 32-6.
130. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009; 30: 679-88.
131. Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 2002; 16: S7-12.
132. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with dietinduced hypercholesterolemia. Circulation 2000; 101: 1586-93.
133. van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens 2007; 25: 2454-62.
134. Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010; 57: 12-25.
135. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
136. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 102: 351-6.
137. Brasier AR, Recinos A 3rd, Eledrisi MS.Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-66.
138. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002; 3: 569-77.
139. Lakshmi SV, Padmaja G, Kuppusamy P, Kutala VK. Oxidative stress in cardiovascular disease. Indian J Biochem Biophys 2009; 46: 421-40.
140. Fukuda D, Sata M, Ishizaka N, Nagai R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90-6.
141. Fukuda D, Sata M. Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol Ther 2008; 118: 268-76.
142. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86: 494-501.
143. Barry-Lane PA, Patterson C, van der Merwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-22.
144. Viedt C, Soto U, Krieger-Brauer HI, et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000; 20: 940-8.
145. Ushio-Fukai M, Alexander RW, Akers M, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274: 22699-704.
146. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000; 87: 1195-201.
147. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-52.
148. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADHoxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-33.
149. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
150. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
151. Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Proinflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007, 85: 462-72.
152. Gibbons GH, Dzau VJ.The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-8.
153. Tousoulis D, Koutsogiannis M, Papageorgiou N, et al. Endothelial dysfunction: potential clinical implications. Minerva Med 2010; 101: 271-84.
154. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-61.
155. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 1995; 96: 141-9.
156. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270: 14214-9.
157. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
158. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84: 695-703.
159. Hahn AW, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178-80.
160. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79: 748-56.
161. Takagishi T, Murahashi N, Azagami S, Morimatsu M, Sasaguri Y. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 1995; 35: 265-73.
162. Scott-Burden ST, Mackie EJ, Buhler FR. Angiotensin II induction of smooth muscle matrix synthesis in culture. J Vasc Med Biol 1991; 3: 271-276.
163. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1419-24.
164. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-74.
165. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
166. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II.Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
167. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-20.
168. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-8.
169. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-72.
170. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury.Possible role in restenosis. J Clin Invest 1994; 93: 339-46.
171. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation. 1994; 90: 449-55.
172. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
173. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 1129-34.
174. Snyder RA, Kaempfer CE, Wintroub BU. Chemistry of a human monocyte-derived cell line (U937): identification of the angiotensin I-converting activity as leukocyte cathepsin G. Blood 1985, 65: 176-82.
175. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem 1991; 266: 19192-7.
176. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C. Angiotensin II induces nuclear factor-kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 2000; 32: 1767-78.
177. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996; 16: 1070-3.
178. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35: 353-9.
179. Rodgers KE, DeCherney AH, St Amand KM, et al. Histologic alterations in dermal repair after thermal injury effects of topical angiotensin II. J Burn Care Rehabil 1997, 18: 381-8.
180. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997, 15: 1295-302.
181. Hoshida S, Kato J, Nishino M, et al. Increased angiotensinconverting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001; 103: 630-3.
182. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ Res 1992; 70: 820-8.
183. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004; 126: 120-6.
184. Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000; 1: 11-7.
185. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101-8.
186. Fukuda D, Sata M. The renin-Angiotensin system: a potential modulator of endothelial progenitor cells. Hypertens Res 2007; 30: 1017-8.
187. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-9.
188. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2004; 18: 203-9.
189. Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. Hum Genet 2009; 125: 467-91.
190. Tsai CT, Hwang JJ, Chiang FT, et al. ATP-binding cassette transporter A1 gene I823M polymorphism affects plasma high-density lipoprotein cholesterol level and modifies the effect of low highdensity lipoprotein cholesterol on the risk of coronary artery disease. Cardiology 2007; 107: 321-8.
191. Ko YL, Ko YS, Wang SM, et al. Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Hum Genet 1997; 100: 210-4.
192. Winkelmann BR, Russ AP, Nauck M, et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999; 137: 698-705.
193. Canavy I, Henry M, Morange PE, et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost 2000, 83: 212-6.
194. Jeunemaitre X, Ledru F, Battaglia S, et al. Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet 1997; 99: 66-73.
195. Wang JG, Staessen JA. Genetic polymorphisms in the reninangiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410: 289-302.
196. van Geel PP, Pinto YM, Zwinderman AH, et al. Increased risk for ischaemic events is related to combined RAS polymorphism. Heart 2001; 85: 458-62.
197. Kretowski A, McFann K, Hokanson JE, et al. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes 2007; 56: 863-71.
198. Brugts JJ, Isaacs A, de Maat MP, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 2011; 29: 509-19.
199. Ragia G, Nikolaidis E, Tavridou A, et al. Renin-angiotensinaldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. J Renin Angiotensin Aldosterone Syst 2010; 11: 136-45.
200. Tsai CT, Hwang JJ, Lai LP, Wang YC, Lin JL, Chiang FT. Interaction of gender, hypertension, and the angiotensinogen gene haplotypes on the risk of coronary artery disease in a large angiographic cohort. Atherosclerosis 2009; 203: 249-56.
201. Gluba A, Banach M, Mikhailidis DP, Rysz J.Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo 2009; 23: 797-812.
202. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008; 31: 596-615.
203. American Diabetes Association. Standards of medical care in diabetes--2009. Diabetes Care 2009; 32: S13-61.
204. Centers for Disease Control and Prevention. Estimates of diagnosed diabetes now available for all US countries 2008.
205. Kim JA, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005; 25: 889-91.
206. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978-85.
207. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005; 288: E353-9.
208. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensinaldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16: 120-6.
209. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 2005; 18: 121-8.
210. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-65.
211. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-10.
212. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-39.
213. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-7.
214. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-707.
215. Lenz O, Fornoni A. Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center. Kidney Int 2008; 74: 851-3.
216. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001; 142: 487-92.
217. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20: 965-73.
218. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007; 12: 147-53.
219. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993; 21: 136-41.
220. Wei Y, Whaley-Connell AT, Chen K, et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-91.
221. Wei Y, Sowers JR, Clark SE, et al. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008; 294: E345-51.
222. Leung PS, de Gasparo M. Involvement of the pancreatic reninangiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 2006; 1: 197-203.
223. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007; 580: 31-7.
224. Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI. Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal 2007; 9: 911-29.
225. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
226. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007; 18: 58-65.
227. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-91.
228. Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289: H813-22.
229. Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 2006; 55: 3594-603.
230. Wei Y, Whaley-Connell AT, Chen K et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-91.
231. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008; 28: 692-7.
232. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man.A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-52.
233. Sjöstrand M, Eriksson JW. Neuroendocrine mechanisms in insulin resistance. Mol Cell Endocrinol 2009; 297: 104-11.
234. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-69.
235. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-8.
236. Tham DM, Martin-McNulty B, Wang YX, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30.
237. Diep QN, Amiri F, Touyz RM, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40: 866-71.
238. Sugawara A, Takeuchi K, Uruno A, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-34.
239. Van Linthout S, Spillmann F, Lorenz M, et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009; 53: 682-7.
240. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993; 118: 273-8.
241. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
242. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
243. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48-53.
244. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
245. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
246. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Antiinflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108: 96-100.
247. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
248. Bokoch GM, Prossnitz V. Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J Clin Invest 1992; 89: 402-8.
249. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterolindependent mechanisms. Ann Med 2003; 35: 398-403.
250. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005 Nov; 46: 1086-92.
251. Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 2008; 124: 149-59.
252. Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-93.
253. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297-305.
254. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-7.
255. Yvan-Charvet L, Quignard-Boulangé A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 2011; 79: 162-8.
256. Dorresteijn JA, Visseren FL, van den Meiracker AH, Spiering W. Obesity-related hypertension. Ned Tijdschr Geneeskd 2011; 154:A1945.
257. Vaidya A, Forman JP, Underwood PC, et al. The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. Eur J Endocrinol 2011; 164: 995-1002.
258. Fu JY, Zhang YM, Zeng LY, Zhang GC, Weng JP. Effects of leptin on RAAS and nitric oxide production in isolated rat glomeruli. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 663-6.
259. Di Murro A, Petramala L, Cotesta D, et al. Renin-angiotensinaldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-72.
260. Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M. The antiproteinuric effect of the blockade of the reninangiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? Nefrologia 2009; 29: 421-9.
261. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
262. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17: 8-13.
263. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens; 15: 389-93.
264. Woodiwiss AJ, Nkeh B, Samani NJ, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J Hypertens 2006; 24: 1057-64.
265. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 72: 169-80.
266. Takei Y, Joss JM, Kloas W, Rankin JC. Identification of angiotensin I in several vertebrate species: its structural and functional evolution. Gen Comp Endocrinol 2004; 135: 286-92.
267. Nibu Y, Takahashi S, Tanimoto K, Murakami K, Fukamizu A. Identification of cell type-dependent enhancer core element located in the 3'-downstream region of the human angiotensinogen gene. J Biol Chem 1994; 269: 28598-605.
268. Merrill DC, Thompson MW, Carney CL, et al. Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest 1996; 97: 1047-55.
269. Ganten D, Wagner J, Zeh K, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992; 89: 7806-10.
270. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979; 1: 287-91.
271. Gardes J, Bouhnik J, Clauser E, Corvol P, Menard J. Role of angiotensinogen in blood pressure homeostasis. Hypertension 1982; 4: 185-9.
272. Ménard J, el Amrani AI, Savoie F, Bouhnik J. Angiotensinogen: an attractive and underrated participant in hypertension and inflammation. Hypertension 1991; 18: 705-7.
273. Ohkubo H, Kawakami H, Kakehi Y, et al. Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci USA 1990; 87: 5153-7.
274. Ward K, Hata A, Jeunemaitre X, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 1993; 4: 59-61.
275. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786-97.
276. Inoue I, Rohrwasser A, Helin C, et al. A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. J Biol Chem 1995; 270: 11430-6.
277. Morgan T, Craven C, Nelson L, Lalouel JM, Ward K. Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest 1997; 100: 1406-15.
278. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003, 23: 1269-75.
279. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A. Role of C/A polymorphism at-20 on the expression of human angiotensinogen gene. Hypertension 1999; 33: 108-15.
280. Narayanan CS, Cui Y, Zhao YY, Zhou J, Kumar A. Orphan receptor Arp-1 binds to the nucleotide sequence located between TATA box and transcriptional initiation site of the human angiotensinogen gene and reduces estrogen induced promoter activity. Mol Cell Endocrinol 1999; 148: 79-86.
281. Morgan L, Crawshaw S, Baker PN, Broughton Pipkin F, Kalsheker N. Polymorphism in oestrogen response element associated with variation in plasma angiotensinogen concentrations in healthy pregnant women. J Hypertens 2000; 18: 553-7.
282. Hilgers KF, Delles C, Veelken R, Schmieder RE. Angiotensinogen gene core promoter variants and non-modulating hypertension. Hypertension 2001; 38: 1250-4.
283. Tiago AD, Samani NJ, Candy GP, et al. Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension. Circulation 2002; 106: 1483-7.
284. Jain S, Tang X, Narayanan CS, et al. Angiotensinogen gene polymorphism at-217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem 2002; 277: 36889-96.
285. Jain S, Li Y, Patil S, Kumar A. A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity. J Mol Med 2005; 83: 121-31.
286. Brand E, Chatelain N, Paillard F, et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet 2002; 10: 715-23.
287. Nakajima T, Jorde LB, Ishigami T, et al. Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations. Am J Hum Genet 2002; 70: 108-23.
288. Zhu X, Chang YP, Yan D, et al. Associations between hypertension and genes in the renin-angiotensin system. Hypertension 2003; 41: 1027-34.
289. Zhu X, Yan D, Cooper RS, et al. Linkage disequilibrium and haplotype diversity in the genes of the renin-angiotensin system: findings from the family blood pressure program. Genome Res 2003; 13: 173-81.
290. Tsai CT, Fallin D, Chiang FT, et al. Angiotensinogen gene haplotype and hypertension: interaction with ACE gene I allele. Hypertension 2003; 41: 9-15.
291. Gu CC, Chang YP, Hunt SC, et al. Haplotype association analysis of AGT variants with hypertension-related traits: the HyperGEN study. Hum Hered 2005; 60: 164-76.
292. Schmidt H, Aulchenko YS, Schweighofer N, et al. Angiotensinogen promoter B-haplotype associated with cerebral small vessel disease enhances basal transcriptional activity. Stroke 2004; 35: 2592-7.
293. Rohrwasser A, Zhang S, Dillon HF, et al. Contribution of Sp1 to initiation of transcription of angiotensinogen. J Hum Genet 2002; 47: 249-56.
294. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011; 32: 2135-42.